Pradefovir, a liver-targeted prodrug of adefovir against HBV infection

Current Opinion in Investigational Drugs

Volumn 8, Issue 8, 2007, Pages 682-690

  Tillmann, Hans L ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; ICN 2001 3; INTERFERON; LAMIVUDINE; MB 06866; NUCLEOSIDE DERIVATIVE; PRADEFOVIR; REMOFOVIR; TELBIVUDINE; TENOFOVIR; THYMOSIN ALPHA1; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; HEPATITIS B; HUMAN; MEDICAL TECHNOLOGY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; HEPATITIS B, CHRONIC; HUMANS; LIVER; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34547647033     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Lamivudine as initial treatment for chronic hepatitis B in the United States. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA N ENGL J MED 1999 341 17 1256-1263
2. Metabasis Therapeutics Inc announces the signing of a development and license agreement for its HepDirect hepatitis B therapeutic with ICN Pharmaceuticals Inc. Metabasis Therapeutics Inc PRESS RELEASE 2001 October 02
3. Form 10-Q. Ribapharm Inc FORM 10-Q 2002 May 28
4. Ribapharm submits investigational New Drug Application for Hepavir B. Ribapharm Inc PRESS RELEASE 2002 October 31
5. Antiviral Research - 16th International Conference (Part I), HBV and HCV, Savannah, GA, USA, 27 April - 1 May 2003. Smee D IDDB MEETING REPORT 2003 April 27 - May 01
6. Antiviral Research - 16th International Conference (Part II), Satellite Symposium: Clinical update on antiviral drugs, Savannah, GA, USA, 27 April - 1 May 2003. Vere Hodge RA IDDB MEETING REPORT 2003 April 27 - May 01
7. Metabasis reports the earning of a milestone payment based on continued development of remofovir for the treatment of hepatitis B. Metabasis Therapeutics Inc PRESS RELEASE 2004 April 16
8. Anadys Pharmaceuticals and LG Life Sciences enter into joint development and license agreement for LB80380 - ANA380 - a phase II hepatitis B compound. Anadys Pharmaceuticals Inc PRESS RELEASE 2004 April 19
9. Metabasis announces second quarter 2004 financial results. Metabasis Therapeutics Inc PRESS RELEASE 2004 August 12
10. Liver-targeted drug delivery using HepDirect prodrugs. Erion MD, van Poelje PD, MacKenna DA, Colby TJ, Montag AC, Fukitaki JM, Linemeyer DL, Bullough DA J PHARMACOL EXP THER 2005 312 2 554-560
11. Pradefovir clinical and pre-clinical results presented at EASL in Paris. Metabasis Therapeutics Inc PRESS RELEASE 2005 April 22
12. 14C] remofovir in rats and cynomolgus monkeys. Lin CC, Xu C, Zhu N, Lourenco D, Yeh LT ANTIMICROB AGENTS CHEMOTHER 2005 49 3 925-930
13. Remofovir mesylate: A prodrug of PMEA with improved livertargeting and safety in rats and monkeys. Lin CC, Yeh LT, Vitarella D, Hong Z, Erion MD ANTIVIR CHEM CHEMOTHER 2004 15 6 307-317
14. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. van Bommel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T HEPATOLOGY 2004 40 6 1421-1425
15. Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Lin CC, Fang C, Benetton S, Xu GF, Yeh LT ANTIMICROB AGENTS CHEMOTHER 2006 50 9 2926-2931
16. Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. Lin CC, Xu C, Teng A, Yeh LT, Peterson J J CLIN PHARMACOL 2005 45 11 1250-1258
17. Valeant Pharmaceuticals and Metabasis Therapeutics license rights to hepatitis B compound pradefovir to Schering-Plough Corporation. Metabasis Therapeutics Inc, Valeant Pharmaceuticals International PRESS RELEASE 2006 December 13
18. Valeant Pharmaceuticals & Metabasis Therapeutics close licensing deal with Schering-Plough Corporation. Metabasis Therapeutics Inc PRESS RELEASE 2007 January 11
19. Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. Nekvindova J, Masek V, Veinlichova A, Anzenbacherova E, Anzenbacher P, Zidek Z, Holy A XENOBIOTICA 2006 36 12 1165-1177
20. Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-Week analysis of a phase 2 study. Lee KS, Lim SG, Chuang WL, Hwang SG, Cho M, Lai MY, Chao YC, Chang TT, Han KH, Lee CM, Um SH et al J HEPATOL 2006 44 Suppl 2 S274
21. A one year trial of lamivudine for chronic hepatitis B. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF N ENGL J MED 1998 339 2 61-68
22. Efficacy of lamivudine in patients with hepatitis B and antigennegative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF HEPATOLOGY 1999 29 3 889-896
23. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N et al J AM MED ASSOC 1999 282 24 2305-2312
24. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, Serpaggi J, Verkarre V, Varaut A, Morales E, Nalpas B, Brosgart C, Pol S TRANSPLANTATION 2005 80 8 1086-1092
25. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, Brosgart CL, Westland C, Arterbrun S, Deray G KIDNEY INT 2004 66 3 1153-1158
26. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. Hezode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, Dhumeaux D, Pawlotsky JM J HEPATOL 2007 46 5 791-796
27. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Lavanchy D J VIRAL HEPAT 2004 11 2 97-107
28. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ GASTROENTEROLOGY 2006 130 3 678-686
29. REVEAL-HBV study group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH J AM MED ASSOC 2006 295 1 65-73
30. Lamivudine for patients with chronic hepatitis B and advanced liver disease. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS et al N ENGL J MED 2004 351 15 1521-1531
31. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP J HEPATOL 2006 45 4 529-538
32. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: A systematic review. Raza SA, Clifford GM, Franceschi S BR J CANCER 2007 96 7 1127-1134
33. Pharmacokinetics and pharmacodynamics of pradefovir mesylate, a liver-targeting pro-drug of PMEA, in HBV patients. Lin C, Xu C, Yeh LT, Sullivan-Bolyai J, Xu Y J HEPATOL 2006 44 Suppl 2 S16
34. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. Sheldon JA, Corral A, Rodes B, Mauss S, Rockstroh J, Berger F, Schwarze-Zander C, Soriano V AIDS 2005 19 17 2036-2038
35. Monitoring the virus load can predict the emergence of drugresistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. Puchhammer-Stockl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, Heinz FX, Watschinger B, Hofmann H J INFECT DIS 2000 181 6 2063-2066
36. Why do we not yet have combination chemotherapy for chronic hepatitis B? Sasadeusz JJ, Locarnini SL, Macdonald G MED J AUST 2007 186 4 204-206
37. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2-year analysis of 650 patients. Lampertico P, Marzano A, Levrero M, Santantonio T, Andreone P, Brunetto M, Di Marco V, Fagioli S, Mazzalla, Raimondo G J HEPATOL 2006 44 Suppl 2 S51
38. Tenofivir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are co-infected with HIV: Results of ACTG A5127. Peters M, Anderson J, Lynch P, Jacobson J, Sherman K, Alston Smith B, Swindells S, Liu T, Johnson V, Pollard R, Rooney J et al INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2005 22 Abs 124
39. A 48-week clevudine therapy demonstrated significant viral suppression and biochemical improvement in naive patients with HBeAg-positive chronic hepatitis B. Chung YH, Lee KS, Kim JH, Ryu SH, Paik SW, Um SH, Han BH, Cho M, Byun KS, Kim BI, Park JW et al SHANGHAI-HONG KONG INT LIVER CONGRESS 2006 Abs 7
40. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. Colonno RJ, Rose RE, Pokorniwski K, Baldick CJ, Eggers B, Yu D, Cross A, Tenney DJ ANN MEET EUR ASSOC STUDY LIVER 2007 Abs 781
41. Metabasis Therapeutics announces first quarter 2007 results and achievements. Metabasis Therapeutics Inc PRESS RELEASE 2007 May 03
42. Phase III study evaluating Gilead's Viread for the treatment of chronic hepatitis B virus meets primary endpoint. Gilead Sciences Inc PRESS RELEASE 2007 June 06
43. Antiviral therapy and resistance with hepatitis B virus infection. Tillmann HL WORLD J GASTROENTEROL 2007 13 1 125-140
44. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. Roche B, Samuel D, Gigou M, Feray C, Virot V, Majno P, Serraf L, David MF, Dusseaix E, Reynes M, Bismuth H J HEPATOL 1999 31 4 584-592
45. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Krüger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, Böker KH, Broelsch CE, Pichlmayr R, Manns MP LIVER TRANSPL SURG 1996 2 4 253-262
46. One year treatment with clevudine demonstrated significant viral suppression and biochemical improvement. Chung YH, Lee KS, Kim JH, Ruy SH, Paik SW, Um SH, Han BH, Cho M, Byun KS, Kim BI, Park JW et al J HEPATOL 2006 44 Suppl 2 S25
47. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS, Taiwan Childhood Hepatoma Study Group N ENGL J MED 1997 336 26 1855-1859
48. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS J PEDIATR 2001 139 3 349-352
49. Hepatitis B virus replication. Beck J, Nassal M WORLD J GASTROENTEROL 2007 13 1 48-64
50. Molecular virology and the development of resistant mutants: Implications for therapy. Locarnini S SEMIN LIVER DIS 2005 25 Suppl 1 9-19
51. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD et al GASTROENTEROLOGY 2003 125 6 1714-1722
52. Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-Carrie N, Barange K, Canva V, Doffoel M, Cales P J HEPATOL 2006 45 3 355-360
53. HBeAg-negative chronic hepatitis B: From obscurity to prominence. Manesis EK J HEPATOL 2006 45 3 343-346
54. HBV resistance determination from the telbivudine GLOBE registration trial. Standring DN, Seifer M, Patty A, Chapron C, Van Doom LJ, Chao G, Brown N, Lai CL ANN MEET EUR ASSOC STUDY LIVER 2006 Abs 541
55. HepSera (adefovir dipivoxil): Product information. Gilead Sciences Inc COMPANY PUBLICATION 2006 October 31
56. Second phase III study evaluating Gilead's Viread for the treatment of chronic hepatitis B virus meets primary endpoint. Gilead Sciences Inc PRESS RELEASE 2007 June 25
57. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. DiBisceglie A, Lai C, Gane E, Chen Y, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Zeuzem S, Rasenack J, Bzowej N et al ANN MEET AM ASSOC STUDY LIVER DIS 2006 Abs 112
58. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Lai C, Gane E, Hsu C, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej, Naoumov N, Zeuzem S et al ANN MEET AM ASSOC STUDY LIVER DIS 2006 Abs 91
59. Metabasis Therapeutics announces CS-917 phase 2b clinical trial results and reports on status of pradefovir. Metabasis Therapeutics Inc PRESS RELEASE 2007 July 17
60. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Cundy KC CLIN PHARMACOKINET 1999 36 2 127-143